EnCap Investments Sells Jupiter Power to BlackRock
15.11.2022 08:00:00 EET | Business Wire | Press release
EnCap Investments L.P. (EnCap) today announced that BlackRock Alternatives (BlackRock), through a fund managed by its Diversified Infrastructure business, has agreed to acquire Jupiter Power LLC (Jupiter), a leading U.S. operator and developer of stand-alone, utility-scale battery energy storage systems.
EnCap Energy Transition Fund I (EETF I) and co-investment partners Yorktown Partners and Mercuria Energy are selling Jupiter, and the transaction is expected to close in late 2022, subject to customary closing conditions.
Since its founding in 2017, Jupiter has focused on proprietary data-driven approaches to large scale, stand-alone energy storage projects designed to meet the growing need for grid support and renewables integration driven by the energy transition. Jupiter’s team includes 70 professionals with more than 25,000 megawatts (MW) of prior power generation project experience globally, including some of the first utility-scale energy storage projects built in the U.S. With that expertise, Jupiter has assembled one of the earliest and most geographically diversified storage development pipelines in the country, totaling over 11,000 MW from California to Maine. The company owns and operates a large storage fleet in Texas comprising 655-megawatt hours (MWh), and currently has 340 MWh of new projects in or near construction, including its first project in California. Earlier in 2022 Jupiter closed a ground-breaking stand-alone storage portfolio debt financing of its operating portfolio and announced a collaboration to secure 2,400 MWh of domestic-content-qualified battery energy storage systems for its 2024-2025 projects.
“Acquisition of Jupiter’s uniquely capable energy storage platform by BlackRock’s Diversified Infrastructure business is another sign that energy storage is maturing into an important new player in the electricity business with a critical role to play,” said Jupiter Power CEO Andy Bowman. “Our team has special insight into the many useful things storage can do because of our deep prior experience with renewable energy projects, and we are proud to help lead the way now to the next generation of utility scale energy storage systems.”
“Jupiter is a pioneer in the utility scale battery energy storage industry in the U.S. We are proud to have been their capital provider and partner as they grew the platform and facilitated the integration of renewables onto the U.S. power grid,” said EnCap Energy Transition Managing Partner Kellie Metcalf, who is also chairwoman of the Jupiter board of directors. “We are excited about the company’s outlook for future success.”
EnCap was an early investor in Jupiter and has been an aggressive provider of capital in the fast-growing U.S. energy storage business since it began pursuing opportunities created by the global transition to a lower-carbon energy system. With EnCap’s financial support and strategic expertise, Jupiter leveraged its early mover development positions, supplier relationships and proprietary dispatch applications to successfully execute its innovative portfolio. This allowed Jupiter to become a leader in bridging the gap between intermittent generation supply and real-time consumer demand for power.
The acquisition of Jupiter by BlackRock’s Diversified Infrastructure business, part of BlackRock Alternatives, is the second exit transaction by EnCap’s $1.2 billion EETF I. In addition to Jupiter, EETF I has backed leading energy transition companies, including Catalyze Energy (distributed commercial and industrial solar plus batteries), Solar Proponent (large scale solar), Triple Oak Power (utility scale wind power) and Arbor Renewable Gas (clean fuels), among others.
White and Case, LLP served as legal advisor and Lazard as financial advisor to the seller, and Simpson Thacher & Bartlett as BlackRock’s legal advisor.
About EnCap Investments L.P.
Since 1988, EnCap Investments has been a leading provider of growth capital to the independent sector of the U.S. energy industry. The firm has raised 22 institutional investment funds totaling approximately $38 billion and currently manages capital on behalf of more than 350 U.S. and international investors. Founded in 2019, the EnCap Energy Transition platform is led by four Managing Partners, each with 25-30 years of experience in the development and operations of renewables and power generation. For more information, please visit www.encapinvestments.com.
About Jupiter Power
Jupiter is a leading battery energy storage infrastructure platform with deep trading, analytics, development, finance, operations, and construction capabilities and unparalleled intellectual property in dispatch optimization. Jupiter is backed by EnCap Investments L.P., Yorktown Partners, and Mercuria Energy, and has offices in Austin and Houston, Texas, and Chicago, Illinois. Jupiter has a 655 MWh portfolio of commercially operating utility-scale battery energy storage projects, 340 MWh of projects currently in or near construction, and a pipeline of over 11,000 MW of new projects in active development. For more information on Jupiter Power, please visit our Twitter, LinkedIn, or Facebook pages or visit www.jupiterpower.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114006002/en/
Contact information
Media Contacts
EnCap Investments
For U.S. media inquiries:
Meredith Howard
Redbird Communications Group
210-737-4478
meredith@redbirdpr.com
For UK/Europe media inquiries:
Philip Walters
+44 (0)7773331589
pwalters@prosek.com
Jupiter Power
Caitlin Smith
512-937-6574
Caitlin.Smith@JupiterPower.io
Media@JupiterPower.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
